Search academic texts

Information × Registration Number 0222U003011, 0122U001590 , R & D reports Title Study of the effectiveness of chronic parenteral therapy viral hepatitis in the dynamics of the application of various direct schemes and indirect influence popup.stage_title Head Fedorchenko Serhii V., д.мед.н. Registration Date 17-02-2022 Organization State Institution "LV Gromashevsky Institute of Epidemiology and Infectious Diseases of the National Academy of Medical Sciences of Ukraine" popup.description2  he study included 921 patients with HCV (41 of them with RAS mutations) and 120 with HCV. In the course of the study it was found that the combination of DAA SOF + LED allowed to achieve CBR in 98.69% of patients with CHC with the 1st HCV genotype. Decrease in liver fibrosis index, recorded by fibrotest and shear wave elastography after 24 weeks. after receiving SOF + LED, reflects the ability of DAA to inhibit fibrogenesis. HTP using the combination of DAA SOF + DAC is highly effective in patients infected with HCV 2nd and 3rd genotypes, CBV reached 100% and 96.1%, respectively. Factors such as patient gender, viral load, presence or absence of previous experience with antiviral therapy, and activity of hepatic ALT / AST enzymes at the start of therapy do not affect the induction of a sustained virological response in patients infected with HCV genotypes 2 and 3. Patients with HCV genotype 3 have a high degree of liver fibrosis, F4, as a factor that worsens the response to therapy. Increasing the duration of SOF + DAC therapy from 12 to 24 weeks. increases the likelihood of STIs in patients with high levels of F4 fibrosis. High efficacy of 3D + SOF + RBV has been demonstrated in patients with HCV subtype 1b infection and cirrhosis who have not previously achieved CAB DAA with first- or second-generation NS5A inhibitors. The degree of fibrosis, the presence of single NS5A RAS (L31M / V / I or Y93H) or dual RAS NS5A (L31M / V and Y93H), and the generation of previously used NS5A inhibitors did not affect the achievement of SVR12 after the use of 3D + SOF + RBV. In Ukraine, genotype D (80%) and A (15%) dominate in patients with HCV. The most common form of HCV is the HBeAg-negative variant of HCV - 82.0%, compared to 18.0% with HBeAg-positive variant of HCV. HBsAg clearance at the end of HTP (48 weeks) was recorded in 7% of patients, three of whom had seroconversion to HBsAg, and at 144 weeks, 9% and 4%, respectively. Positive predictors of response to PEG INF therap Product Description popup.authors Klimenko Zhanna B Lyashok Olga V Martinovich Tatiana L Marcinowski Vadim M Solyanyk Iryna V popup.nrat_date 2022-03-09 Close